X
<

Can Intuitive Surgical Sustain Its Current Stock Rally?

PART:
1 2 3 4
Can Intuitive Surgical Sustain Its Current Stock Rally? PART 1 OF 4

Intuitive Surgical Traded at a 52-Week High on October 5

Stock performance

Intuitive Surgical (ISRG), the leader in minimally invasive robotics surgery, has seen tremendous growth lately. It was trading at its 52-week high of $1,094.55 on October 5, 2017. The stock closed at $1,089.75 that day. That compares to the stock’s 50-day moving average of $1,021.32 and 200-day moving average of $914.17.

Intuitive Surgical Traded at a 52-Week High on October 5

Interested in ISRG? Don't miss the next report.

Receive e-mail alerts for new research on ISRG

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Intuitive Surgical registered its 2Q17 earnings results on July 20, 2017. ISRG stock rose that day since the company registered stellar results, exceeding Wall Street analysts’ estimates. ISRG stock has risen 12.2% since the 2Q17 earnings release. The company is set to announce its 3Q17 earnings results on October 19, 2017. That might trigger a movement in ISRG stock that day. The PowerShares QQQ ETF (QQQ) might also be impacted. ISRG accounts for ~0.60% of QQQ‘s total holdings.

Intuitive Surgical has registered a YTD (year-to-date) return of 71.0%. The return surpasses the US medical device industry’s (IHI) return of 27.6% for the same period.

As of October 5, 2017, peers Medtronic (MDT), Edwards Lifesciences (EW), and Stryker (SYK) rose 12.6%, 19.0%, and 23.0%, respectively, on a YTD basis.

Intuitive Surgical’s stock performance driven by strong fundamentals

Intuitive Surgical’s leadership position in the market and strong business model are some of the major factors driving the company’s growth. The company is continually striving to introduce innovative products in the minimally invasive robotics surgery space. With the recent launches of da Vinci X and da Vinci Sp, the company expects to increase its market share. Although the company’s market position is under threat from impending competition from Medtronic and Johnson & Johnson in the long term, the company is not likely to face any major near-term competition.

X

Please select a profession that best describes you: